Helsinn, a Swiss pharmaceutical company, makes a drug using specific doses of palonosetron for treating nausea and vomiting caused by chemotherapy and acquired patents covering this drug. Teva sought FDA approval to market a generic version of the Helsinn drug, and Helsinn sued Teva for patent infringement. Teva alleged the asserted patent claims were invalid under § 102(a)(1) over a prior sale.
About two years before the effective filing date of Helsinn’s asserted patents, Helsinn entered agreements with a U.S.-based pharmaceutical company, MGI Pharma, in which Helsinn agreed to supply any palonosetron products approved by the FDA to MGI Pharma. In exchange, Helsinn received up-front royalty payments and exclusivity. MGI Pharma also agreed to maintain as confidential Helsinn’s proprietary information. Because the formulation claimed in Helsinn’s patents was not revealed to the public prior to patenting, the district court determined that the on-sale bar did not apply, but the Federal Circuit reversed.
The Supreme Court affirmed the Federal Circuit’s judgment. In doing so, the Court noted that the Patent Act has included an on-sale bar since 1836 and pre-AIA precedent applying the “on-sale” bar did not require public disclosure. The Court looked to precedent, including Pfaff v. Well Electronics, Inc., 525 U.S. 55, 67 (1998) and Federal Circuit cases holding that secret sales may qualify as invalidating prior art, to support the proposition that “on sale” had a “well-settled meaning” prior to the AIA’s enactment. According to the Court, under that settled meaning, sales or offers for sale “need not make an invention available to the public” to qualify as prior art.
The Court further concluded the AIA did not change the meaning of “on sale.” As amended by the AIA, section 102(a) provides, “[a] person shall be entitled to a patent unless … the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.” Helsinn relied on the catchall phrase “or otherwise available to the public” to suggest that Congress intended to alter the meaning of “on sale” to require public availability. The Supreme Court disagreed, saying this addition “was simply not enough of a change” to show Congressional intent to change the meaning of “on sale.”
This is an important decision for both patent applicants and litigants. Applicants and patentees need to be cognizant of agreements and activities with third parties that could trigger the “on sale” bar. Such activities, which might not bar a patent application in other jurisdictions, may qualify as prior art under U.S. law. In disputes involving post-AIA patents, this decision may open the door to additional prior art defenses for accused infringers, for which patentees need to be prepared.